ClinicalTrials.gg
TerminatedNCT03173092Updated May 4, 2026

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

A Phase 4 interventional study of Ixazomib and Lenalidomide in Multiple Myeloma, sponsored by Takeda. Terminated at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Why this study was terminated
All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
141
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies testing ixazomib in Multiple Myeloma — 1 open to participants now, 7 under way, none of them phase 3. ixazomib · Multiple Myeloma.

Enrollment
12th of 68
141 · median 48
Started
2017
with 4 others
Phase 4
4 of 68
1 open now
Registered
41st of 68
by date
Lead sponsor
10 of 68
Takeda

Among the 68 studies testing ixazomib in Multiple Myeloma, this one is the 12th largest by enrollment, is one of 5 that started in 2017, is one of 4 in phase 4, and was the 41st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 68 studies testing ixazomib in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ixazomib

ixazomib: first FDA approval 2015 (NINLARO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies testing ixazomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction regimen.

The study will enroll approximately 160 participants, who are enrolled after completing 3 cycles of chemotherapy (Bortezomib-Based Induction Regimen). They are then treated with Ixazomib in addition to lenalidomide and dexamethasone.

Read the detailed description

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have MM. This study will look at the effectiveness and safety in participants who take the all-oral combination of ixazomib added to lenalidomide and dexamethasone.

The study will enroll approximately 160 participants. Participants will initially receive:

  • Ixazomib 4 mg + lenalidomide 25 mg + dexamethasone 40 mg

Participants include MM participants who have received 3 cycles of a bortezomib-based induction regimen (as defined by current National Comprehensive Cancer Network [NCCN] guidelines) and have no evidence of PD following initial first-line therapy. All participants will be asked to take ixazomib 4 mg on Days 1, 8 and 15 and lenalidomide 25 mg from Day 1 through 21 and dexamethasone 40 mg on Days 1, 8, 15 and 22 in 28 day cycles until disease progression or unacceptable toxicity for up to 3 years.

Dose modifications of ixazomib, and/or lenalidomide and/or dexamethasone are allowed at the discretion of the physician.

This multi-center trial will be conducted in United States. It is anticipated that the treatment phase of this study will last up to 78 months, including 42 months for enrollment, and a 36-month IRD treatment period (39 cycles) with ixazomib and/or lenalidomide and/or dexamethasone for the last participant enrolled.

Participants will make multiple visits to the clinic as per their standard of care, and will be followed for PFS. After disease progression, participants will be followed-up for overall survival every 6 months until death or termination of the study by the sponsor.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have a diagnosis of a MM using current IMWG diagnostic criteria and have received 1 .

    • Participants must have completed 3 cycles of a bortezomib-based induction regimen (as defined by current NCCN guidelines) and have no evidence of disease progression as defined by IMWG criteria.
    • Participants with light chain and free light chain (FLC) only may be enrolled if they meet all the criteria for a diagnosis of MM.
    • Participants must be considered by their physician eligible to receiving the IRD regimen.
  2. Must be transplant ineligible as determined by their physician, or if transplant eligible, not expect to undergo transplant for at least 24 months after study enrollment.

    o Stem cell harvest and mobilization regimen is acceptable if clinically indicated, but must first be confirmed by the Takeda Medical Monitor.

  3. (ECOG) performance status and/or other performance status 0, 1, or 2 at time of enrollment.
  4. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice 2 effective methods of , at the same time, from the time of signing the form through 90 days after the last dose of study drug, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence [example, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
  5. Male participants, even if surgically sterilized (that is, status post-vasectomy), must agree to one of the following:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence (example, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).

Exclusion criteria

Exclusion Criteria:

  1. Participation in other interventional clinical trials, including those with other agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial. Non-interventional trials (that is, observational trials) are permitted at any time point.
  2. Failure to have fully recovered (that is, less than or equal to [\<=] Grade 1 toxicity) from the reversible effects of prior chemotherapy.
  3. Major surgery within 14 days before enrollment.
  4. Radiotherapy within 14 days before enrollment (if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib).
  5. Central nervous system involvement by MM.
  6. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
  7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
  8. Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450 3A () inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.
  9. Ongoing or active systemic infection, active or C virus infection, or known positive.
  10. Diagnosed or treated for another within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  11. Has greater than or equal to (>=) Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during the screening period.
  12. Have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not.
  13. PD on therapy.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg

    Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs first for up to 3 years.

    Drug: Ixazomib · Drug: Lenalidomide · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as time from date of first administration of study drug regimen to date of first documentation of progressive disease (PD) based on local laboratory results and investigator's assessment using modified International Myeloma Working Group (IMWG) response criteria or death due to any cause, whichever occurs first.

    Time frame: From date of first study drug administration until disease progression or death due to any cause, whichever occurs first (Up to 2 years).

Secondary outcomes

  1. Percentage of Participants with Partial Response (PR), Very Good Partial Response (VGPR) and Complete Response (CR)

    Response is based on investigator's assessment using modified IMWG criteria.

    Time frame: Day 1 of each cycle (every 28 days) until disease progression for up to 3 years.

  2. Duration of Response

    Duration of response is defined as the time from the date of first documentation of a PR or better to the date of first documentation of PD for responders.

    Time frame: Day 1 of each cycle (every 28 days) until disease progression for up to 3 years.

  3. Duration of Treatment (DoT)

    DoT is defined as the time from the date of the first administration of the study drug regimen (IRD) to the date of the last administration of any of the 3 study drugs in the regimen.

    Time frame: From the date of the first study drug administration to the date of the last administration of any of the 3 study drugs (Up to 3 years).

  4. Duration of Ixazomib Therapy

    Duration of ixazomib therapy is defined as the time from the date of the first administration of ixazomib therapy to the date of the last administration of ixazomib therapy.

    Time frame: From the date of the first ixazomib administration to the date of the last ixazomib administration (Up to 3 years).

  5. Relative Dose Intensity (RDI) for Each Study Drug

    RDI for each study drug is defined as 100\*(Total amount of dose taken)/(Total prescribed dose of treated cycles), where total prescribed dose equals \[dose prescribed at enrollment \* number of prescribed doses per cycle \* the number of treated cycles\].

    Time frame: Up to 3 years

  6. Duration of Proteasome Inhibitor Therapy

    Duration of proteasome inhibitor therapy is defined as the time from the date of the first administration of bortezomib based therapy to the date of the last administration of the study drug (ixazomib).

    Time frame: Up to 3 years.

07

Study locations

21 sites
  • Arizona Oncology Associates
    Tucson, Arizona 85704, United States
  • Los Angeles Cancer Network/(Formerly -Pacific Cancer Medical Center)
    Anaheim, California 92801-1824, United States
  • Compassionate Care Research Group, Inc.
    Fountain Valley, California 92708, United States
  • Innovative Clinical Research
    Santa Ana, California 92705, United States
  • US Oncology Research
    Colorado Springs, Colorado 80907, United States
  • Woodlands Medical Specialists- Pensacola
    Pensacola, Florida 32503, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30303-001, United States
  • Investigator Clinical Research - Indiana
    Indianapolis, Indiana 46260-2082, United States
  • Saint Agnes Hospital
    Baltimore, Maryland 21229, United States
  • American Oncology Partners of Maryland P.A
    Bethesda, Maryland 20817, United States
  • Central Care Cancer Center
    Bolivar, Missouri 65613, United States
  • Kansas City Veterans Affairs Medical Center
    Kansas City, Missouri 64128, United States
  • Comprehensive Cancer Center of Nevada
    Henderson, Nevada 89074, United States
  • Tri-Health Cancer Institute-Medical Oncology and Hematology Westside
    Cincinnati, Ohio 45247, United States
  • Willamette Valley Cancer Institute and Research Center - Springfield
    Springfield, Oregon 97477, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • Texas Oncology- Presbyterian Cancer Center Dallas
    Dallas, Texas 75231, United States
  • Texas Oncology-San Antonio Northwest
    San Antonio, Texas 78240, United States
  • Millennium Physicians Association
    Shenandoah, Texas 77380-3256, United States
  • Texas Oncology -Tyler
    Tyler, Texas 75702, United States
08

References and documents

Publications

  • Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, Richter J, Abonour R, Lee HC, Stokes M, Ren K, Stull DM, Cherepanov D, Bogard K, Noga SJ, Girnius S. In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. Future Oncol. 2024 Jan;20(3):131-143. doi: 10.2217/fon-2023-0272. Epub 2023 Oct 9. PubMed 37807952 ↗

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2026, 100 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2017
First posted
Jun 1, 2017
StartActual
Nov 13, 2017
Primary completionActual
Mar 30, 2026
CompletionActual
Mar 30, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03173092
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 1, 2017
Start date
Nov 13, 2017
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
May 4, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixazomib · Lenalidomide · Dexamethasone

Start the discussion